Welcome to our dedicated page for Equillium news (Ticker: EQ), a resource for investors and traders seeking the latest updates and insights on Equillium stock.
Equillium, Inc. (Nasdaq: EQ) is a La Jolla, California–based clinical-stage biotechnology company that publicly describes its focus as developing novel therapies for severe autoimmune and inflammatory disorders. News about Equillium often centers on the progress of its lead candidate EQ504, an investigational aryl hydrocarbon receptor (AhR) modulator, and on corporate actions that support its development strategy.
Readers of this EQ news page can follow company announcements on clinical and preclinical plans for EQ504, including preparations for Phase 1 studies in ulcerative colitis and related gastrointestinal conditions, as well as potential applications in inflammatory lung or pulmonary diseases. Equillium’s press releases also highlight scientific and translational updates, such as key opinion leader events discussing AhR modulation, intestinal inflammation and the unmet medical need in ulcerative colitis.
In addition to pipeline news, Equillium regularly reports on financing transactions like private placements and at-the-market offerings, which it links to funding the development of EQ504 and extending its operating runway. Corporate governance and leadership updates, including changes in board composition, committee membership and senior roles, are disclosed through both SEC filings and news releases.
Another recurring topic in Equillium’s news flow is its cryptocurrency treasury reserve strategy, which the company has described as part of its broader financial and growth objectives. Updates in this area appear alongside information on cash resources, investment policy changes and strategic priorities.
Investors and observers can use this news feed to monitor Equillium’s clinical plans, scientific positioning around AhR modulation, capital-raising activities, Nasdaq listing developments and treasury strategy, all of which shape the company’s path as a clinical-stage biotech focused on immuno-inflammatory diseases.
Equillium, Inc. (Nasdaq: EQ), a clinical-stage biotechnology firm, will present at the H.C. Wainwright Autoimmune & Inflammatory Disease Virtual Conference on Thursday, March 30, at 10:30 am PT. The presentation will focus on the company's expertise in autoimmune diseases and its lead candidate, EQ101, a tri-specific cytokine inhibitor targeting IL-2, IL-9, and IL-15, currently in a Phase 2 study for alopecia areata. Management will also be available for one-on-one meetings. A live webcast will be accessible on the company's website, with a replay available for 90 days.
Equillium, Inc. (Nasdaq: EQ) has announced positive results from its EQUATE study on Itolizumab, a targeted therapy for acute graft-versus-host disease (aGVHD). The presentation at the American Society of Transplantation and Cellular Therapy showed high clinical response rates with a 70% reduction in steroid use at Day 29 and a remarkable 99% taper at Day 169. These findings suggest potential for Itolizumab as a first-line treatment in severe aGVHD, with the initiation of the pivotal Phase 3 EQUATOR study.
Dr. Koreth emphasized the significance of these results, considering the lack of approved first-line treatments for aGVHD.
Equillium, Inc. (NASDAQ: EQ) announced its participation in the SVB Securities Global Biopharma Conference on February 14 at 10:00 am PT. The presentation will cover the recent partnership with Ono Pharmaceuticals and details on its multi-cytokine inhibitor platform, including EQ101 for alopecia areata and EQ102 for celiac disease. Management will also discuss upcoming catalysts and will be available for one-on-one meetings. The webcast can be accessed via the Investor Relations section of Equillium’s website, and a replay will be available for 90 days.
Equillium, Inc. (Nasdaq: EQ) announced that an abstract was accepted for oral presentation at the Transplantation & Cellular Therapy Meetings, taking place from February 15-19, 2023, in Orlando, Florida. The presentation, titled "Final Safety and Efficacy Results from EQUATE," details the promising findings of a Phase 1b study of itolizumab for treating newly diagnosed acute graft-versus-host disease (aGVHD).
The study shows significant outcomes, including long-term follow-ups up to one year. Following these results, Equillium has initiated EQUATOR, a Phase 3 study to evaluate itolizumab as a potential first-line treatment.
Equillium, Inc. (Nasdaq: EQ) and Metacrine, Inc. have mutually terminated their merger agreement, originally aimed at enhancing cash reserves. CEO Bruce Steel stated that a recent partnership with Ono Pharmaceutical will extend Equillium's financial runway into 2025, allowing focus on its pipeline of multi-cytokine inhibitors. The strategic shift emphasizes confidence in its clinical programs, including EQ101 and Itolizumab, which target severe autoimmune disorders. Further details can be found in Equillium's Current Report on Form 8-K.
Equillium, Inc. (NASDAQ: EQ) announced the initiation of a Phase 2 clinical study of itolizumab in collaboration with Biocon Limited for treating ulcerative colitis (UC) in India. This double-blinded, placebo-controlled trial aims to evaluate the safety and efficacy of itolizumab compared to adalimumab in biologics-naïve patients. The study will enroll up to 90 patients and is designed to provide insights into itolizumab's potential benefits. Itolizumab, a first-in-class anti-CD6 monoclonal antibody, has shown promise in earlier studies on severe acute graft-versus-host disease.
Equillium, Inc. (Nasdaq: EQ) announced positive interim results from the EQUALISE study of itolizumab in lupus nephritis, with 83% of patients achieving a complete or partial response and 67% showing over 80% reduction in urine protein creatinine ratio by week 28. The company also confirmed the acquisition of Metacrine, expected to add $35 million in cash to its balance sheet, extending its operating runway into 2024. Additionally, Equillium initiated Phase 2 and Phase 1 studies for EQ101 and EQ102, respectively, targeting alopecia areata and celiac disease.
Equillium, Inc. (Nasdaq: EQ) presented key research at ACR Convergence, indicating that urinary soluble ALCAM (sALCAM) may serve as a biomarker for disease severity in lupus nephritis (LN), potentially aiding in treatment response assessment. This study aligns urinary ALCAM levels with existing measures of LN, suggesting a less invasive alternative to kidney biopsies. Dr. Maple Fung highlighted its significance for patient monitoring. Itolizumab, Equillium's first-in-class monoclonal antibody, targets the CD6-ALCAM pathway and is currently undergoing clinical studies for its effectiveness in treating severe autoimmune disorders.
Equillium has launched a Phase 2 proof-of-concept study for EQ101 targeting alopecia areata, a common autoimmune condition. This open-label trial will involve approximately 30 adult subjects in Australia over 24 weeks, assessing efficacy, safety, tolerability, and pharmacokinetics. EQ101 inhibits key cytokines IL-2, IL-9, and IL-15, potentially offering a more selective treatment than current options. Previous studies indicated EQ101's safety and effectiveness in related conditions. The study's results are anticipated in 2023, marking a significant advancement in Equillium's pipeline.